U.S. FDA to reconvene experts’ meeting for Amylyx’s ALS drug

(Reuters) – Amylyx Pharmaceuticals said on Tuesday the U.S. Food and Drug Administration will reconvene a meeting of its outside experts to review the company’s application seeking approval for its amyotrophic lateral sclerosis treatment.

The meeting will be held on Sept. 7.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Vinay Dwivedi)